pharma news today obesity glp-1 health drugs october 2025 Outlook for obesity in 2025: more Most people know GLP-1 medications

Learn more about our editorial standards and meet the medical team

Users who feel persistently tired on their medication should evaluate their fluid intake before attributing fatigue solely to the drug itself

Small Molecule Amylin Mimetics: Companies are developing oral formulations of amylin analogues

If GLP-1 medications reduce these risks, even partially, the implications for long-term lupus management are profound

These results suggested the possibility of GLP-1 as a treatment for diabetes, but limitations for therapeutic utility existed as endogenous GLP-1 had a short half-life in plasma of 1 to 2 minutes, degraded by the dipeptidyl-peptidase 4 (DPP-4) enzyme [13]

Giugliano D, Maiorino MI, Bellastella G, et al